glp-1 agonists and sglt2 inhibitors Criteria for recommendation of or receptor Cardiorenal Protection: Potential of SGLT2
Description
Another subcutaneous injectable version (WEGOVY) is approved for the same indication of obesity or overweight with at least one weight-related comorbidity, in combination with diet and exercise [31,32,33]
On the other hand, product uptake is through the roof
(2019) 42(Suppl 1):S90102
Ozempic
The impact of obesity on IBD onset and progression is an area of growing research, though evidence remains controversial
GIP adds metabolic improvements through pancreatic and fat tissue effects
